Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

Amerikaanse aandelen Terug naar discussie overzicht

HOT stocks vandaag.

12.177 Posts
Pagina: «« 1 ... 586 587 588 589 590 ... 609 »» | Laatste | Omlaag ↓
  1. [verwijderd] 22 oktober 2014 12:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    hosternokke schreef op 22 oktober 2014 03:02:

    [...]

    IBIO, NLNK en INO houd ik in de gaten. Maar enkel om eventueel te day traden, en dan in kleine porties. Don't get greedy.
    Ik ga straks ook weer wat IBIO op pikken voor een trade.Grote kans dat het weer up gaat vandaag.Hopelijk loopt die in de pre markt niet te ver op.
    Die van 1,30 doe ik nog niet weg, als er plots goed nieuws valt dan gaat die als een speer omhoog.
    Die wil ik niet missen.
  3. [verwijderd] 22 oktober 2014 14:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0



    IBIO NEWS!!!!! IBio Expands Exclusive Product Collaboration With Novici Biotech

    Quote:NEWARK, DE, Oct 22, 2014 (Marketwired via COMTEX) -- iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products, to include iBio's proprietary IBIO-CFB03 product for idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases. This expanded program will combine the strength of the iBioLaunch(TM) platform with Novici's patented GRAMMR(R) technology for rapid evolution of gene sequences to significantly increase expression yield of target proteins.
    IBIO-CFB03 and related proteins have been produced in plants on the iBioLaunch platform substantially more quickly and cost-effectively than has been possible with traditional methods. By combining the strengths of the iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive production efficiency even further as the fibrosis team initiates expanded animal testing and additional IND-enabling tasks.

    In April 2013, iBio announced the achievement of a technology transfer milestone when Novici was able to use the iBioLaunch system in a challenge study, without any involvement of iBio, to reliably replicate production of commercial yields of targeted biotherapeutics and vaccines. An additional benchmark was achieved in a second live-fire study in May 2013 when Novici used iBioLaunch technology to produce a recombinant vaccine candidate for H7N9 influenza within 21 days of receiving initial antigen sequence information from iBio. Subsequently, the two companies have worked together on iBio-proprietary and third party antibody product candidates addressing both chronic therapy and acute infectious disease treatment.

    Novici has previously applied GRAMMR technology successfully for gene and protein optimization to rapidly increase the expression yields of certain target products without alteration of the structure and function of the proteins themselves. By increasing the efficiency with which a desired product can be manufactured, without changing the characteristic of the product or established downstream purification processes, manufacturing capacity of existing facilities can be increased when needed to address pandemic or bioterrorism threats or other urgent needs without the costs and time required to enlarge existing or build additional facilities.
  4. [verwijderd] 23 oktober 2014 00:49

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Mapp Biopharmaceuticals’ experimental Ebola drug ZMapp is perhaps the most advanced drug to date, and is also on the WHO’s list for the trial candidates. However, supplies of the drug have been exhausted. The company is currently looking for different ways to increase production, one of which is collaboration with Caliber Biotherapeutics and Ibio Inc (IBIO)

    www.bidnessetc.com/27717-tekmira-gain...
  5. [verwijderd] 23 oktober 2014 00:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Today's news prooves IBIO is working on EBOLA

    iBio Expands Exclusive Product Collaboration With Novici Biotech

    "iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, and Novici Biotech LLC (Novici) have agreed to broaden their commercial collaboration, currently focused on antibodies and certain vaccine products"

    money.cnn.com/news/newsfeeds/articles...

    ---------------------------------
    Now this>>>>
    U.S. Will Increase Production of the Ebola Drug ZMapp, but May Not Meet Demand

    "Mapp is said to be working with another small company, Novici Biotech, which has a method of tweaking the genetic instructions for the antibodies in a way that could boost production."

    www.nytimes.com/2014/10/02/world/us-t...
  8. [verwijderd] 23 oktober 2014 16:41

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Researchers racing to develop a vaccine that could help halt the Ebola epidemic are getting good news: Early human clinical trials of one leading candidate, involving small groups of volunteers in the United States and Europe, suggest that the vaccine is safe.

    www.washingtonpost.com/national/healt...

  19. [verwijderd] 23 oktober 2014 22:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Goe hedaan boys.
    Morgen misschien ook weer een ritje proberen. Do- en vrijdag lijken gunstige handelsdagen voor IBIO.

    Da's m'n hele aanvalsplan. Niet eens een notendop.
    Ha, ha, ha.
  20. [verwijderd] 23 oktober 2014 23:31

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against iBio, Inc. – IBIO

    Ibio, Inc. (AMEX:IBIO)

    Today : Thursday 23 October 2014

    The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against iBio, Inc. (NYSE: IBIO).

    On October 9, 2014, the Washington Post reported that the manufacturer of the experimental Ebola drug ZMapp was seeking additional production capacity from Caliber Biotherapeutics (“Caliber”). On October 16, 2014, iBio issued a press release titled “iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak”, which (among other things) “confirmed [] the applicability of its issued U.S. iBio Launch platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus” and that it had been working with Caliber. iBio further “offered to assist the U.S. government by making its proprietary technology available [to] address the current Ebola virus outbreak”.

    On October 17, 2014, it was announced that U.S. officials had asked the A&M Lab and two others to submit plans to produce the experimental Ebola drug ZMapp. Also on October 17, an iBio spokesperson was quoted as saying that any lab that wants to make ZMapp vaccine using plant-based technology would have to license it from iBio.

    On October 20 and 23, 2014, reports were published online revealing that (a) iBio’s relationship with Caliber had nothing to do with an Ebola drug, (b) rival Icon Genetics AG had created a method to produce ZMapp using plant-based technology and need not license technology from iBio, and (c) the head of the A&M Lab had stated that any plant-based ZMapp manufacturing method would have to be identical to what the maker of the drug had already vetted in animals, ruling out different methods like iBio's.

    On these adverse disclosures, iBio’s stock fell from $3.21 to $1.59, damaging investors.

    As result of these adverse disclosures the Rosen Law Firm is preparing a securities class action on behalf of iBio shareholders. If you purchased iBio securities after October 10, 2014, please visit the website at www.rosenlegal.com/cases-409.html. You may also contact Phillip Kim, Esq., or Jonathan Horne, Esq., toll-free, at 866-767-3653; or by email at pkim@rosenlegal.com or jhorne@rosenlegal.com, for information on the class action.

    The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

    Attorney Advertising. Prior results do not guarantee a similar outcome.

    The Rosen Law Firm, P.A.
    Laurence M. Rosen, Esq.
    Phillip Kim, Esq.
    Jonathan Horne, Esq.
    275 Madison Avenue 34th Floor
    New York, New York 10016
    Tel: 212-686-1060
    Toll Free: 1-866-767-3653
    Fax: 212-202-3827
    lrosen@rosenlegal.com
    pkim@rosenlegal.com
    jhorne@rosenlegal.com
    www.rosenlegal.com
12.177 Posts
Pagina: «« 1 ... 586 587 588 589 590 ... 609 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.510
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.580
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.720
Aedifica 3 903
Aegon 3.258 322.685
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.329
Air France - KLM 1.025 35.022
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.685
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.907
AMG 971 133.194
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 490
Antonov 22.632 153.605
Aperam 92 14.969
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.766
Arcelor Mittal 2.033 320.656
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.289
Aroundtown SA 1 219
Arrowhead Research 5 9.729
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.088
ASML 1.766 106.375
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392